肿瘤免疫治疗中不可忽视的免疫相关不良反应

A review of immune-related adverse events associated with immunotherapy

免疫检查点抑制剂已在我国被批准进入临床应用,随之而来的免疫相关不良反应(irAE)需引起临床医师的关注。文章总结了针对抗程序性细胞死亡蛋白和程序性细胞死亡蛋白配体抗体引起的irAE发病率、特征性临床表现以及治疗方法,探讨了其可能的发病机理、不同类型恶性肿瘤发病率的差别、影响因素以及未来的研究方向,为临床肿瘤医师对肿瘤irAE的识别和监控加以指导。

Immune checkpoint inhibitors have been approved for clinical application in China.However,the increased immune-related adverse event(irAE)needs more attention.This review summarized the incidence,characteristic clinical manifestation and treatment of irAEs associated with programmed cell death protein-1(PD-1)and programmed cell death ligand-1(PD-L1)inhibitors.To have a deep insight into irAE,the potential mechanisms,the different incidences of cancer types,influencing factors and the direction of future research were also discussed here to provide guidance for clinical oncologist to identify and monitor irAE.